Anti-aging Therapeutics Market - Distribution by Type of Molecule (Biologics and Small Molecules), Type of Aging (Cellular Aging, Immune Aging, Metabolic Aging and Others) and Key Geographies (North America, Europe, Asia Pacific, and Rest of the World) – Industry Trends and Global Forecasts, 2022-2040

  • Lowest Price Guaranteed From USD 5,899

  • Published
    June 2022

  • Pages
    180

  • View Count
    330

Example Insights

Anti-aging-Therapeutics-Market-Context-thumb Anti-aging-Therapeutics-Market-List-of-Anti-aging-thumb Anti-aging-Therapeutics-Market-Distribution-by-Phase-of-Development-thumb Anti-aging-Therapeutics-Market-Company-Competitiveness-Analysis-thumb
Anti-aging-Therapeutics-Market-Partnerships-and-Collaborations-thumb Anti-aging-Therapeutics-Market-Funding-and-Investments-thumb Anti-aging-Therapeutics-Market-Patent-Analysis-thumb Anti-aging-Therapeutics-Market-Publication-Analysis-thumb
Anti-aging-Therapeutics-Market-Porter-s-Five-Forces-Analysis-thumb Anti-aging-Therapeutics-Market-Distribution-by-Geography-thumb    

Overview

The advancements in health care and available technologies have inadvertently led to an increase in the life expectancy of individuals. However, this has also led to a rise in the aging population worldwide. According to the United Nations, the aforementioned trend is one of the key transformations observed in the 21st century; it is expected to have an impact on all sections of the society. Aging is linked to a variety of diseases, including cardiovascular disorders, neurodegenerative disorders, oncological disorders and musculoskeletal disorders, which further puts heavy economic and psychological burden on the patients, their families and the society. As per the World Health Organization, in 2020, close to 1 billion people were estimated to be aged 65 or above, globally. In addition, the share of elderly population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging biology is still a largely unexplored field, in terms of the development of safe and effective novel pharmacotherapies. Anti-aging therapeutics, therefore, is an emerging field of medical science focused on reducing or reversing the underlying causes of aging through different mechanisms, in order to extend healthy lifespan of humans.

Given the rapidly growing aging population, the ongoing efforts to discover drugs that enhance the lifespan of an individual by targeting the pathogenesis of aging have become a popular topic for research. At present, various anti-aging products and devices, including direct-to-consumer nutraceuticals, plastic surgeries, cosmetics, skincare products and devices, are available in the market to slow the process of aging. Further, several start-ups and academic / research institutes across the world are evaluating various types of anti-aging therapeutics, including stem cell therapies, metformin, rapamycin, resveratrol and senolytics (drugs that selectively clear senescent cells), in multiple preclinical / clinical studies. Owing to the encouraging results demonstrating the ability of novel drugs in delaying the aging process, capital investments worth USD 4 billion have been made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid to long-term.

Scope of the Report

The “Anti-aging Therapeutics Market - Distribution by Type of Molecule (Biologics and Small Molecules), Type of Aging (Cellular Aging, Immune Aging, Metabolic Aging and Others) and Key Geographies (North America, Europe, Asia Pacific, and Rest of the World) – Industry Trends and Global Forecasts, 2022-2040” report features an extensive study of the current market landscape and future potential of anti-aging therapeutics over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of anti-aging therapeutics, featuring information on phase of development (commercial, phase II, phase I / II, phase I, clinical (phase unknown), discovery / preclinical and undisclosed), type of aging (cellular aging, metabolic aging, immune aging, others and undisclosed), type of molecule (biologics and small molecules), mechanism of action (senolytic, cell regeneration, mammalian target of rapamycin (mTOR) inhibitor / modulator, adenosine monophosphate (AMP)-kinase / AMP activator, mitochondria inhibitor / modulator and others) and type of developer (industry and non-industry). In addition, the chapter features analyses of anti-aging therapeutic developers based on parameters, such as year of establishment, company size, location of headquarters and leading developers (in terms of number of pipeline candidates)
  • A competitiveness analysis of anti-aging therapeutic developers, based on various relevant parameters, namely supplier power (based on the experience of the developer) and company competitiveness (based on highest phase of development, type of aging and type of molecule).
  • An analysis of partnerships that have been inked by stakeholders engaged in this domain, during the period 2018-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, most active players (in terms of number of partnerships), type of partner and regional distribution of collaborations.
  • A detailed analysis of investments that have been made into companies which are developing proprietary anti-aging therapeutics, during period 2018-2022. The various types of funding instances reported in this domain include pre-seed financing, seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants, crowdfunding, and donations.  
  • An in-depth analysis of the various patents that have been filed / granted related to anti-aging therapeutics, during 2018-2022, taking into consideration parameters, such as publication year, type of patent, geographical region, CPC symbols, key focus areas, type of applicant, patent age and leading players (in terms of size of intellectual property portfolio). It also features a patent benchmarking analysis and a detailed valuation analysis.
  • A detailed review of more than 220 peer-reviewed, scientific articles related to research on anti-aging therapeutics, during the period 2018-2022, based on several relevant parameters, such as year of publication, type of publication, popular keywords and geography of affiliations. The chapter also provides information on the most popular publisher, most popular journal, most popular affiliations and most popular funding institutes (in terms of number of articles published)
  • A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.
  • Elaborate profiles of prominent players engaged in the development of anti-aging therapeutics, featuring a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for anti-aging therapeutics, during the time period 2022-2040. The report also includes likely sales forecasts of anti-aging therapeutics that are in the mid to late stages of development. Additionally, it features market size projections for the overall anti-aging therapeutics market, wherein both the current and upcoming opportunity is segmented across [A] type of molecule (biologics and small molecules), [B] type of aging (cellular aging, immune aging, metabolic aging and others) and [C] key geographies (North America, Europe, Asia Pacific, and Rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Peter Fedichev (Co-Founder and Chief Executive Officer, Gero.AI)
  • James Clement (President, Betterhumans)  
  • Wee Kiat Tan (Chief Operating Officer, CytoMed Therapeutics)
  • Rosa Argyropoulos (Senior Director of Global Corporate Communications, Cambrian Biopharma)
  • Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist, Landmark Medical Centre)

Key Questions Answered

  • Who are the leading players engaged in the development of anti-aging therapeutics?
  • What types of partnership models are commonly adopted by industry stakeholders engaged in this industry?
  • Who are the key investors in the anti-aging therapeutics domain?
  • How is the intellectual property landscape in this field likely to evolve in the foreseen future?
  • What is the evolving trend of publications focused on anti-aging therapeutics?
  • What are the key value drivers that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our report. It offers a high-level view of the current state of anti-aging therapeutics market and its likely evolution in the short term, mid-term and long term.

Chapter 3 provides a general introduction to the aging process. In addition, the chapter features information on the types and causes of aging. It also presents an elaborate description of the mechanism of action adopted by anti-aging therapeutics. Further, it highlights various diseases related to aging, as well as discusses the key facts and future perspectives associated with anti-aging therapeutics.

Chapter 4 features a detailed review of the current market landscape of anti-aging therapeutics, featuring information on phase of development (commercial, phase II, phase I / II, phase I, clinical (phase unknown), discovery / preclinical and undisclosed), type of aging (cellular aging, metabolic aging, immune aging, others and undisclosed), type of molecule (biologics and small molecules), mechanism of action (senolytic, cell regeneration, mTOR inhibitor / modulator, AMP-kinase / AMP activator, mitochondria inhibitor / modulator and others) and type of developer (industry and non-industry). In addition, the chapter presents analysis related to anti-aging therapeutic developers based on parameters, such as year of establishment, company size, location of headquarters and leading developers (in terms of number of pipeline candidates).

Chapter 5 presents a detailed competitiveness analysis of anti-aging therapeutics developers, based on various relevant parameters, namely supplier power (based on the experience of the developer) and company competitiveness (based on highest phase of development, type of aging and type of molecule).

Chapter 6 provides an elaborate discussion and analysis of the various collaborations and partnerships inked between stakeholders engaged in this domain, in the period 2018-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (research and development agreements, product / technology licensing agreements, research agreements, acquisitions, mergers and joint ventures), most active player(s) (in terms of number of partnerships inked), type of partner and regional distribution (continent and country-wise) of collaborations.

Chapter 7 provides details on the various investments and grants that have been awarded to players focused on the development of anti-aging therapeutics. It includes a detailed analysis of the funding instances that have taken place during the period 2018-2022, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 8 presents an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to anti-aging therapeutics, during 2018-2022, taking into consideration parameters, such as publication year, type of patent, geographical region, CPC symbols, patent focus areas, type of applicant, patent age and leading players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 9 consists of a detailed analysis of more than 220 peer-reviewed, scientific articles related to research on anti-aging therapeutics, during the period 2018-2022, based on several relevant parameters, such as year of publication, type of publication, popular keywords and geography of affiliations. The chapter also provides information on the most popular publishers, most popular journals, most popular affiliations and most popular funding institutes (in terms of number of articles published).

Chapter 10 provides insights on a qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.

Chapter 11 includes brief profiles of prominent players engaged in the development of anti-aging therapeutics. Each profile features a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook.

Chapter 12 features an elaborate discussion on the future commercial opportunity offered by anti-aging therapeutics. It provides a comprehensive market forecast analysis for molecules that are in phase II and above development stages taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapeutics. The chapter also presents a detailed market segmentation on the basis of [A] type of molecule (biologics and small molecules), [B] type of aging (cellular aging, immune aging, metabolic aging and others), and [C] key geographies (North America, Europe, Asia Pacific, and Rest of the world).

Chapter 13 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Peter Fedichev (Co-Founder and Chief Executive Officer, Gero.AI), James Clement (President, Betterhumans), Wee Kiat Tan (Chief Operating Officer, CytoMed Therapeutics), Rosa Argyropoulos (Senior Director of Global Corporate Communications, Cambrian Biopharma) and Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist, Landmark Medical Centre)

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Aging
3.2. Types of Aging
3.3. Causes of Aging
3.4 Mechanism of Action of Anti-aging Therapeutics 
3.5 Age-related Diseases
3.6 Key Facts Associated with Aging
3.7 Future Perspectives of Anti-aging Therapeutics

4. MARKET LANDSCAPE
4.1. Anti-aging Therapeutics: Overall Market Landscape
4.1.1. Analysis by Phase of Development
4.1.2. Analysis by Type of Aging
4.1.3. Analysis by Phase of Development and Type of Aging
4.1.4. Analysis by Type of Molecule
4.1.5. Analysis by Mechanism of Action 
4.1.6. Analysis by Type of Developers

4.2. Anti-aging Therapeutics: Developer Landscape
4.2.1. Analysis by Year of Establishment 
4.2.2. Analysis by Company Size and Location of Headquarters
4.2.3. Leading Developers by Number of Therapeutics
4.2.4. Regional Landscape of Developers

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Anti-aging Therapeutics: Company Competitiveness Analysis
5.4.1. Small Companies
5.4.2. Mid-sized and Large Companies

6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Anti-aging Therapeutics: Partnerships and Collaborations
6.2.1 Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership 
6.2.4. Leading Players: Analysis by Number of Partnerships
6.2.5. Analysis by Type of Partner
6.2.6. Analysis by Type of Agreement
6.2.7. Analysis by Region
6.2.7.1. Intercontinental and Intracontinental Deals
6.2.7.2. International and Local Deals

7. FUNDING AND INVESTMENTS
7.1. Chapter Overview
7.2. Anti-aging Therapeutics: Funding and Investments
7.2.1. Analysis of Instances by Year
7.2.2. Analysis of Amount Invested by Year
7.2.3 Analysis of Instances by Type of Funding 
7.2.4. Analysis of Amount Invested by Type of Funding 
7.2.5. Analysis by Type of Investor
7.2.6. Analysis by Focus Area
7.2.7. Analysis of Amount Invested by Region
7.2.8. Analysis of Amount Invested by Country
7.2.9. Most Active Investors: Analysis by Number of Instances
7.2.10. Most Active Players: Analysis by Number of Instances
7.2.11. Most Active Players: Analysis by Amount Invested

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Anti-aging Therapeutics: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Patent Publication Year
8.3.3. Analysis of Granted Patents by Year
8.3.4. Analysis by Geography
8.3.5. Analysis by CPC Symbols
8.3.6. Analysis by Type of Applicant
8.3.7. Analysis by Emerging Focus Areas
8.3.8. Analysis by Patent Age
8.3.9. Leading Industry Players: Analysis by Number of Patents
8.3.10. Leading Non-Industry Players: Analysis by Number of Patents
8.3.11. Leading Individual Assignees: Analysis by Number of Patents

8.4. Anti-aging Therapeutics: Patent Benchmarking
8.4.1. Analysis by Patent Characteristics
8.5. Anti-aging Therapeutics: Patent Valuation

9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Anti-aging Therapeutics: Publication Analysis
9.3.1. Analysis by Year of Publication
9.3.2. Analysis by Type of Publication
9.3.3. Most Popular Journals: Analysis by Number of Publications
9.3.4. Most Popular Journals: Analysis by Impact Factor
9.3.5. Analysis by Most Popular Keywords
9.3.6. Most Popular Funding Institutes: Analysis by Number of Publications
9.3.7. Most Active Publisher: Analysis by Number of Publications
9.3.8. Most Popular Affiliation: Analysis by Number of Publications
9.3.9. Analysis by Geography

10. PORTER’S FIVE FORCES ANALYSIS
10.1. Chapter Overview
10.2. Methodology and Key Parameters
10.3. Porter’s Five Forces
10.3.1. Threat of New Entrants
10.3.2. Bargaining Power of End Users
10.3.3. Bargaining Power of Drug Developers
10.3.4. Threat of Substitute Products 
10.3.5. Rivalry Among Existing Competitors 

11. COMPANY PROFILES
11.1. AgelessRx
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.3. Recent Developments and Future Outlook

11.2. ANOVA Institute for Regenerative Medicine
11.2.1. Company Overview
11.2.2. Product Portfolio
11.2.3. Recent Developments and Future Outlook

11.3. Betterhumans
11.3.1. Company Overview
11.3.2. Product Portfolio
11.3.3. Recent Developments and Future Outlook

11.4. BioAge Labs
11.4.1. Company Overview
11.4.2. Product Portfolio
11.4.3. Recent Developments and Future Outlook

11.5. bioXcellerator
11.5.1. Company Overview
11.5.2. Product Portfolio
11.5.3. Recent Developments and Future Outlook

11.6. Cambrian Biopharma
11.6.1. Company Overview
11.6.2. Product Portfolio
11.6.3. Recent Developments and Future Outlook

11.7. Gero.ai
11.7.1. Company Overview
11.7.2. Product Portfolio
11.7.3. Recent Developments and Future Outlook

11.8. Mayo Clinic
11.8.1. Company Overview
11.8.2. Product Portfolio
11.8.3. Recent Developments and Future Outlook

11.9. Rejuvenate Bio
11.9.1. Company Overview
11.9.2. Product Portfolio
11.9.3. Recent Developments and Future Outlook

11.10. UT Health San Antonio
11.10.1. Company Overview
11.10.2. Product Portfolio
11.10.3. Recent Developments and Future Outlook

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Forecast Methodology and Key Assumptions
12.2. Global Anti-aging Therapeutics Market, 2022-2040
12.2.1. Anti-aging Therapeutics Market: Analysis by Type of Molecule
12.2.2. Anti-aging Therapeutics Market: Analysis by Type of Aging

12.2.3. Anti-aging Therapeutics Market: Analysis by Geography
12.2.3.1. Anti-aging Therapeutics Market in North America, 2022-2040
12.2.3.2. Anti-aging Therapeutics Market in Europe, 2022-2040
12.2.3.3. Anti-aging Therapeutics Market in Asia Pacific, 2022-2040
12.2.3.4. Anti-aging Therapeutics Market in Rest of the World, 2022-2040

12.2.4. Anti-aging Therapeutics: Forecast of Individual Product Sales
12.2.4.1. bioXgel (PRP) (bioXcellerator): Estimated Sales Revenues
12.2.4.2. AR-100 (Rejenevie Therapeutics): Estimated Sales Revenues
12.2.4.3. BGE-117 (BioAge Labs): Estimated Sales Revenues
12.2.4.4. Dasatinib and Quercetin (TruDiagnostic): Estimated Sales Revenues
12.2.4.5. MYMD-1 (MyMD Pharmaceuticals): Estimated Sales Revenues
12.2.4.6. TRIIM Treatment (Intervene Immune): Estimated Sales Revenues
12.2.4.7. Rapamycin (AgelessRx): Estimated Sales Revenues
12.2.4.8. Sarconeos (BIO101) (Biophytis): Estimated Sales Revenues

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Gero.ai
13.2.1 Company Snapshot
13.2.2. Interview Transcript: Peter Fedichev (Co-founder and Chief Executive Officer)

13.3. Betterhumans
13.3.1. Company Snapshot
13.3.2. Interview Transcript: James Clement (President)

13.4. CytoMed Therapeutics
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Wee Kiat Tan (Chief Operating Officer)

13.5. Cambrian Biopharma
13.5.1 Company Snapshot
13.5.2. Interview Transcript: Rosa Argyropoulos (Senior Director of Global Corporate Communications)

13.6. Landmark Medical Centre
13.6.1 Company Snapshot
13.6.2. Interview Transcript: Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist)

14. APPENDIX I: TABULATED DATA

15. APPENDIX I1: LIST OF COMAPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Funding and Investment Analysis
Figure 2.4 Executive Summary: Patent Analysis
Figure 2.5 Executive Summary: Publication Analysis
Figure 2.6 Executive Summary: Market Forecast
Figure 3.1 Types of Aging
Figure 3.2 Causes of Aging
Figure 3.3 Mechanism of Action of Anti-aging Therapeutics
Figure 3.4 Age-related Diseases
Figure 4.1 Anti-aging Therapeutics: Distribution by Phase of Development
Figure 4.2 Anti-aging Therapeutics: Distribution by Type of Aging
Figure 4.3 Anti-aging Therapeutics: Distribution by Phase of Development and Type of Aging
Figure 4.4 Anti-aging Therapeutics: Distribution by Type of Molecule
Figure 4.5 Anti-aging Therapeutics: Distribution by Mechanism of Action
Figure 4.6 Anti-aging Therapeutics Developers: Distribution by Type of Developers
Figure 4.7 Anti-aging Therapeutics Developers: Distribution by Year of Establishment
Figure 4.8 Anti-aging Therapeutics Developers: Distribution by Company Size and Location of Headquarters
Figure 4.9 Leading Developers: Distribution by Number of Therapeutics
Figure 4.10 Anti-aging Therapeutics Developers: Regional Landscape
Figure 5.1 Company Competitiveness Analysis: Small Companies
Figure 5.2 Company Competitiveness Analysis: Mid-sized and Large Companies
Figure 6.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 6.4 Leading Players: Distribution by Number of Partnerships
Figure 6.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 6.6 Partnerships and Collaborations: Distribution by Type of Agreement
Figure 6.7 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 6.8 Partnerships and Collaborations: International and Local Deals
Figure 7.1 Funding and Investments: Distribution of Instances by Year
Figure 7.2 Funding and Investments: Distribution of Amount Invested by Year
Figure 7.3 Funding and Investments: Year-wise Distribution of Amount Invested by Type of Funding
Figure 7.4 Funding and Investments: Distribution of Instances by Type of Funding
Figure 7.5 Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 7.6 Funding and Investments: Distribution by Type of Investor
Figure 7.7 Funding and Investments: Distribution by Focus Area
Figure 7.8 Funding and Investments: Distribution of Amount Invested by Region
Figure 7.9 Funding and Investments: Distribution of Amount Invested by Country
Figure 7.10 Most Active Investors: Distribution by Number of Instances
Figure 7.11 Most Active Players: Distribution by Number of Instances
Figure 7.12 Most Active Players: Distribution by Amount Invested
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Distribution by Patent Publication Year
Figure 8.3 Patent Analysis: Distribution of Granted Patents by Year
Figure 8.4 Patent Analysis: Distribution by Geography
Figure 8.5 Patent Analysis: Distribution by CPC Symbols
Figure 8.6 Patent Analysis: Distribution by Type of Applicant
Figure 8.7 Patent Analysis: Emerging Focus Area
Figure 8.8 Patent Analysis: Distribution by Patent Age
Figure 8.9 Leading Industry Players: Distribution by Number of Patents
Figure 8.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.11 Leading Individual Assignees: Distribution by Number of Patents
Figure 8.12 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 8.13 Anti-aging Therapeutics: Patent Valuation
Figure 9.1 Publication Analysis: Distribution by Year of Publication
Figure 9.2 Publication Analysis: Distribution by Type of Publication
Figure 9.3 Most Popular Journals: Distribution by Number of Publications
Figure 9.4 Most Popular Journals: Distribution by Impact Factor
Figure 9.5 Publication Analysis: Most Popular Keywords
Figure 9.6 Most Popular Funding Institutes: Distribution by Number of Publications
Figure 9.7 Most Active Publisher: Distribution by Number of Publications
Figure 9.8 Most Popular Affiliation: Distribution by Number of Publications
Figure 9.9 Publication Analysis: Distribution by Geography
Figure 10.1 Anti-aging Therapeutics: Porter’s Five Forces Analysis
Figure 12.1 Global Anti-aging Therapeutics Market, 2035-2040 (USD Million)
Figure 12.2 Anti-aging Therapeutics Market: Distribution by Type of Molecule, 2022 and 2040 (USD Million)
Figure 12.3 Anti-aging Therapeutics Market: Distribution by Type of Aging, 2022 and 2040 (USD Million)
Figure 12.4 Anti-aging Therapeutics Market: Distribution by Geography, 2022 and 2040 (USD Million)
Figure 12.5 Anti-aging Therapeutics Market in North America, 2022-2040 (USD Million)
Figure 12.6 Anti-aging Therapeutics Market in Europe, 2022-2040 (USD Million)
Figure 12.7 Anti-aging Therapeutics Market in Asia Pacific, 2022-2040 (USD Million)
Figure 12.8 Anti-aging Therapeutics Market in Rest of the World, 2022-2040 (USD Million)
Figure 12.9 bioXgel (PRP) (bioXcellerator): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.10 AR-100 (Rejenevie Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.11 BGE-117 (BioAge Labs): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.12 Dasatinib and Quercetin (TruDiagnostic): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.13 MYMD-1 (MyMD Pharmaceuticals): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.14 TRIIM Treatment (Intervene Immune): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.15 Rapamycin (AgelessRx): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Figure 12.16 Sarconeos (BIO101) (Biophytis): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)

List Of Tables

Table 4.1 List of Anti-aging Therapeutics
Table 4.2 List of Anti-aging Therapeutics Developers
Table 6.1 Anti-aging Therapeutics: List of Partnerships and Collaborations
Table 7.1 Anti-aging Therapeutics: List of Funding and Investments
Table 8.1 Anti-aging Therapeutics: List of Patents
Table 8.2 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 9.1 Anti-aging Therapeutics: List of Publications
Table 11.1 AgelessRx: Product Portfolio
Table 11.2 AgelessRx: Recent Developments and Future Outlook
Table 11.3 ANOVA Institute for Regenerative Medicine: Product Portfolio
Table 11.4 Betterhumans: Product Portfolio
Table 11.5 Betterhumans: Recent Developments and Future Outlook
Table 11.6 BioAge Labs: Product Portfolio
Table 11.7 BioAge Labs: Recent Developments and Future Outlook
Table 11.8 bioXcellerator: Product Portfolio
Table 11.9 Cambrian Biopharma: Product Portfolio
Table 11.10 Cambrian Biopharma: Recent Developments and Future Outlook
Table 11.11 Gero.ai: Product Portfolio
Table 11.12 Gero.ai: Recent Developments and Future Outlook
Table 11.13 Mayo Clinic: Product Portfolio
Table 11.14 Mayo Clinic: Recent Developments and Future Outlook
Table 11.15 Rejuvenate Bio: Product Portfolio
Table 11.16 Rejuvenate Bio: Recent Developments and Future Outlook
Table 11.17 UT Health San Antonio: Product Portfolio
Table 11.18 UT Health San Antonio: Recent Developments and Future Outlook
Table 14.1 Market Landscape: Distribution by Phase of Development
Table 14.2 Market Landscape: Distribution by Type of Aging
Table 14.3 Market Landscape: Distribution by Phase of Development and Type of Aging
Table 14.4 Market Landscape: Distribution by Type of Molecule
Table 14.5 Market Landscape: Distribution by Mechanism of Action
Table 14.6 Developer Landscape: Distribution by Type of Developers
Table 14.7 Developer Landscape: Distribution by Year of Establishment
Table 14.8 Developer Landscape: Distribution by Company Size and Location of Headquarters
Table 14.9 Leading Developers: Distribution by Number of Therapeutics
Table 14.10 Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.11 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.12 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.13 Leading Players: Distribution by Number of Partnerships
Table 14.14 Partnerships and Collaborations: Distribution by Type of Partner
Table 14.15 Partnerships and Collaborations: Distribution by Type of Agreement
Table 14.16 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 14.17 Partnerships and Collaborations: International and Local Deals
Table 14.18 Funding and Investments: Distribution of Instances by Year
Table 14.19 Funding and Investments: Distribution of Amount Invested by Year
Table 14.20 Funding and Investments: Year-wise Distribution of Amount Invested by Type of Funding
Table 14.21 Funding and Investments: Distribution of Instances by Type of Funding
Table 14.22 Funding and Investments: Distribution of Amount Invested by Type of Funding
Table 14.23 Funding and Investments: Distribution by Type of Investor
Table 14.24 Funding and Investments: Distribution by Focus Area
Table 14.25 Funding and Investments: Distribution of Amount Invested by Region
Table 14.26 Funding and Investments: Distribution of Amount Invested by Country
Table 14.27 Most Active Investors: Distribution by Number of Instances
Table 14.28 Most Active Players: Distribution by Number of Instances
Table 14.29 Most Active Players: Distribution by Amount Invested
Table 14.30 Patent Analysis: Distribution by Type of Patent
Table 14.31 Patent Analysis: Distribution by Patent Publication Year
Table 14.32 Patent Analysis: Distribution of Granted Patents by Year
Table 14.33 Patent Analysis: Distribution by Geography
Table 14.34 Patent Analysis: Distribution by Type of Applicant
Table 14.35 Patent Analysis: Distribution by Patent Age
Table 14.36 Leading Industry Players: Distribution by Number of Patents
Table 14.37 Leading Non-Industry Players: Distribution by Number of Patents
Table 14.38 Leading Individual Assignees: Distribution by Number of Patents
Table 14.39 Anti-aging Therapeutics: Patent Valuation
Table 14.40 Publication Analysis: Distribution by Year of Publication
Table 14.41 Publication Analysis: Distribution by Type of Publication
Table 14.42 Most Popular Journals: Distribution by Number of Publications
Table 14.43 Most Popular Journals: Distribution by Impact Factor
Table 14.44 Most Popular Funding Institutes: Distribution by Number of Publications
Table 14.45 Most Active Publisher: Distribution by Number of Publications
Table 14.46 Most Popular Affiliation: Distribution by Number of Publications
Table 14.47 Publication Analysis: Distribution by Geography
Table 14.48 Global Anti-aging Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2035-2040 (USD Million)
Table 14.49 Anti-aging Therapeutics Market: Distribution by Type of Molecule, 2022 and 2040 (USD Million)
Table 14.50 Anti-aging Therapeutics Market: Distribution by Type of Aging, 2022 and 2040 (USD Million)
Table 14.51 Anti-aging Therapeutics Market: Distribution by Geography, 2022 and 2040 (USD Million)
Table 14.52 Anti-aging Therapeutics Market in North America, 2022-2040 (USD Million)
Table 14.53 Anti-aging Therapeutics Market in Europe, 2022-2040 (USD Million)
Table 14.54 Anti-aging Therapeutics Market in Asia Pacific, 2022-2040 (USD Million)
Table 14.55 Anti-aging Therapeutics Market in Rest of the World, 2022-2040 (USD Million)
Table 14.56 bioXgel (PRP) (bioXcellerator): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.57 AR-100 (Rejenevie Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.58 BGE-117 (BioAge Labs): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.59 Dasatinib and Quercetin (TruDiagnostic): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.60 MYMD-1 (MyMD Pharmaceuticals): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.61 TRIIM Treatment (Intervene Immune): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.62 Rapamycin (AgelessRx): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
Table 14.63 Sarconeos (BIO101) (Biophytis): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. Advancells
  2. AgelessRx
  3. AgeX Therapeutics
  4. Albert Einstein College of Medicine
  5. Albert Ludwig University of Freiburg
  6. Altos Labs
  7. Amorepacific
  8. Anhui Agricultural University
  9. ANOVA Institute for Regenerative Medicine
  10. Antoxerene (Subsidiary of Ichor Therapeutics)
  11. Astellas Pharma
  12. Baylor College of Medicine
  13. Beihua University
  14. Betterhumans
  15. BioAge Labs
  16. Biophytis
  17. Bioquark
  18. BioXcellerator
  19. Brigham and Women's Hospital
  20. Buck Institute for Research on Aging
  21. Cambrian Biopharma
  22. Carnegie Mellon University
  23. Case Western Reserve University School of Medicine
  24. Cedars-Sinai Medical Center
  25. cellvie
  26. Centaura
  27. Central South University
  28. Chia Nan University of Pharmacy and Science
  29. Chinese Academy of Medical Sciences
  30. Chongqing University of Education
  31. Cleara Biotech
  32. Cornell University
  33. Cosmax
  34. Covalent Bioscience
  35. CytoMed Therapeutics
  36. Dorian Therapeutics 
  37. ETTA Biotechnology
  38. European Research Council (ERC)
  39. Florica Therapeutics
  40. Fountain Therapeutics
  41. FoxBio 
  42. Georgia Institute of Technology
  43. Gero.ai
  44. Gerostate Alpha
  45. Gray Matter
  46. Grifols
  47. Gustave Roussy
  48. Hackensack Meridian Health
  49. Harvard T.H. Chan School of Public Health
  50. HCW Biologics
  51. Huazhong University of Science and Technology
  52. Inserm
  53. Insilico Medicine
  54. Intervene Immune
  55. Jilin University
  56. Johns Hopkins University
  57. Jumpstart Fertility (Subsidiary of Life Biosciences)
  58. Juvenescence 
  59. Korea Research Institute of Bioscience and Biotechnology (KRIBB)
  60. Landmark Medical Centre (LMC)
  61. Life Biosciences
  62. Longevica
  63. Louisiana State University (LSU)
  64. Lunella Biotech
  65. LyGenesis
  66. Massachusetts General Hospital
  67. Mayo Clinic
  68. Medical University of Graz
  69. Ministry of Education, University and Research (MIUR)
  70. Montefiore Medical Center
  71. MyMD Pharmaceuticals 
  72. Nanna Therapeutics (Acquired by Astellas Pharma)
  73. National Institute on Aging
  74. National Institutes of Health (NIH)
  75. National Natural Science Foundation of China
  76. Navitor Pharmaceuticals
  77. Neopharm
  78. NewLimit
  79. Office of Research Infrastructure Programs
  80. Northeastern University
  81. Northwestern University
  82. Nuritas
  83. Nurosene
  84. Oisin Biotechnologies
  85. Oklahoma Medical Research Foundation (OMRF)
  86. Okyanos Center for Regenerative Medicine
  87. Orthogen
  88. Peking University
  89. Perelman School of Medicine at the University of Pennsylvania 
  90. Rejenevie Therapeutics
  91. Rejuvenate Bio
  92. Rejuveron Life Sciences
  93. Repair Biotechnologies
  94. resTORbio
  95. Sanford Burnham Prebys Medical Discovery Institute
  96. Selphagy Therapeutics (Subsidiary of Life Biosciences)
  97. SENISCA
  98. Senolytic Therapeutics (Subsidiary of Life Biosciences)
  99. Shanghai Bohui Biological Technology
  100. Shanghai Jiao Tong University
  101. Shift Bioscience
  102. Shimadzu Scientific Instruments (Subsidiary of Shimadzu)
  103. Shiseido
  104. Sloan Kettering Institute (SKI)
  105. South Florida Bone Marrow/Stem Cell Transplant Institute
  106. Spring Discovery
  107. Springs Rejuvenation
  108. Stanford University
  109. Stony Brook University
  110. Sun Yat-sen University
  111. Taisho Pharmaceutical
  112. TCI
  113. The Pennsylvania State University
  114. The Rockefeller University
  115. UT Health San Antonio
  116. The University of Texas McGovern Medical School
  117. TruDiagnostic
  118. Tufts University
  119. Turn Biotechnologies
  120. UNITY Biotechnology
  121. University of California
  122. University of California, Berkeley (UCB)
  123. University of California, San Francisco (UCSF)
  124. University of Colorado
  125. University of Massachusetts Medical School
  126. University of Minnesota
  127. University of North Carolina at Chapel Hill
  128. University of Southern California
  129. University of Texas Southwestern Medical Center
  130. University of Wisconsin-Madison
  131. Vanderbilt University
  132. Velabs Therapeutics
  133. Washington University
  134. Wellcome Trust
  135. Whitehead Institute for Biomedical Research
  136. Yale University
  137. Zhejiang Huitai Life Health Technology

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com